Last year's oral sustained controlled release preparations TOP10, the first three are such drugs!

In recent years, under the background of the complex economic environment at home and abroad and the slowdown in the development of the pharmaceutical industry, many pharmaceutical companies have set their sights on the research and development

At the same time, oral sustained-release formulations also have many advantages over common common preparations, such as:

The blood concentration is maintained within the effective therapeutic concentration range for a long time, thereby reducing the frequency of administration and improving the patient's medication compliance

Stabilize blood concentrations, reduce peak-valley effects, and reduce side effects

Increases the stability of treatment and improves efficacy

Reduces irritation to the local gastrointestinal tract during absorption of the drug

To this end, oral sustained and controlled-release preparations are widely used in chronic diseases that require long-term medication, including the cardiovascular and cerebrovascular system (hypertension, hyperlipidemia, etc.

In 2021, China's three major terminals and 6 major markets oral sustained-release preparation TOP10 products

(Source: Intranet Data)

Nifedipine controlled-release tablets

Nifedipine is a dihydropyridine calcium ion antagonist, which is an peripheral and coronary vasodilator that can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or drug-induced coronary artery spasm, increase the delivery of myocardial oxygen in patients with coronary artery spasm, and relieve and prevent coronary artery spasm

Nifedipine controlled-release tablets were originally developed by Bayer Agne in Germany, the trade name is Adamat, which was first listed in Germany in 1993, and is mainly used clinically for the treatment of hypertension, coronary heart disease, chronic stable angina (exertional angina) and so

It is reported that metoprolol is the world's first selective β1 receptor blocker, its affinity for β1 receptors is more than 20 times that of β2 receptors, which can effectively reduce the risk of bronchoconstriction, reduce blood pressure, and prevent the cardiotoxic effects of catecholamines

Metoprolol succinate extended-release tablets were developed by AstraZeneca and first marketed in 1992 under the trade name Betalek, which are mainly used for various types of hypertension and angina

Felodipine is a dihydropyridine calcium channel antagonist (calcium channel blocker), which can reduce blood pressure due to a decrease in peripheral vascular resistance, and play an antiangina role

Felodipine extended-release tablets, originally from AstraZeneca and traded as boidine, were marketed in the United States in 1991 and are mainly used for the treatment of hypertension and stable angina